Aktie A0MUFS THE UNITED LABORATORIES INTERNATIONAL HOLDINGS LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen The United Laboratories International Holdings Limited

Aktien

A0MUFS

KYG8813K1085

3933

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:20 26.04.2024 		% 5 Tage % 1. Jan.
9,48 HKD -2,97 % Intraday Chart für The United Laboratories International Holdings Limited -1,15 % +35,24 %
27.03. The United Laboratories International Holdings Limited meldet die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr CI
27.03. The United Laboratories International's 2023 Gewinn steigt dank höherer Umsätze MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
The United Laboratories International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023
The United Laboratories International's 2023 Profit Rises on Higher Revenue
The United Laboratories International Holdings Limited Recommends Payment of Final Dividend for the Year Ended 31 December 2023
The United Laboratories International Holdings Limited Recommends Payment of Special Dividend for the Year Ended 31 December 2023
The United Laboratories International Forecasts Profit Surge in 2023
The United Laboratories International Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023
United Laboratories Postpones EGM Due to Bad Weather
United Laboratories Subsidiary Gets US FDA Nod for Injectable for Diabetes; Shares Rise 8%
The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection
The United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023
United Laboratories Controlling Shareholder to Sell 64 Million Shares
United Laboratories International Unit Gets Regulatory Nod to Conduct Trial on TUL01101 Tablets
Chinese Regulator Allows Clinical Trial of United Laboratories' Fatty-Liver Drug
The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection
United Laboratories International Says Two Products Pass Consistency Evaluation
China Greenlights United Laboratories' Clinical Trial for Obesity Injection; Shares Rise 4%
The United Laboratories International Holdings Limited Announces Approval for Clinical Trial of Ubt251 Injection on Indication of Overweight or Obesity
The United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023
United Laboratories' H1 Profit Doubles; Shares Fall 4%
The United Laboratories International Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0MUFS Aktie
  4. Nachrichten The United Laboratories International Holdings Limited
  5. Andere Sprachen